Healthy volunteers needed to test safety of experimental drug DF5112
NCT ID NCT07232121
First seen Nov 18, 2025 · Last updated Jun 09, 2026 · Updated 26 times
Summary
This early-stage study tests the safety and tolerability of a new drug, DF5112, in 48 healthy adults aged 18 to 55. Participants receive either the drug or a placebo by injection and are monitored for about a week in a clinic, with follow-up visits through day 29. The goal is to see how the body processes the drug and if it causes any side effects, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT MALE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Scientia Clinical Research Ltd
RECRUITINGSydney, New South Wales, 2031, Australia
Contact
Conditions
Explore the condition pages connected to this study.